SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on speculation that SELLASs Phase 3 REGAL AML trial is nearing its final event trigger and subsequent topline analysis, with traders reacting to CEO commentary and favorable remarks from pharmaceutical-industry professionals. The community remains sharply divided: bulls view the prolonged survival and outside commentary as supportive, while bears question the trial design, delayed event timing, and likelihood of a successful readout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Preliminary second-quarter results showing sharply improved operating profitability despite lower revenue, together with an amended convertible-note exchange that limits stock issuance and shifts the remainder to cash, are driving attention. Traders are divided between viewing the developments as evidence of improving fundamentals and reduced dilution risk, and focusing on revenue declines, management concerns, and unusual warrant activity that has fueled speculative squeeze discussion.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Celina, Texass reported conversion of its city WiFi into Helium-powered carrier coverage is driving attention, with traders viewing the deployment and broader carrier-offload use case as evidence of real-world DePIN adoption. Bullish commenters expect continued momentum, while skeptics question token dilution, hotspot profitability, and whether network usage will translate into value for HNT holders.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Anticipation of broader federal marijuana rescheduling to Schedule III, including an upcoming administrative-law recommendation, is driving attention as traders expect reduced tax burdens and improved institutional access for U.S. cannabis operators. The community remains largely bullish on Trulieves positioning and NYSE listing, while others warn that the catalyst is not yet finalized and cite profit-taking, overbought conditions, and post-earnings concerns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Strong Phase 3 data for CAN-2409 in localized prostate cancer, along with anticipation of ASTRO findings and a planned Q4 BLA submission, is driving bullish attention. Traders see potential regulatory and pharmaceutical-partnership upside, while skeptics point to dilution risk, the unfiled BLA, profit-taking, and broader biotech momentumincluding enthusiasm around cancer-vaccine developmentsas competing factors.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Reports of renewed U.S.-Iran hostilities, tanker attacks, and severely disrupted Strait of Hormuz flows are driving attention to USO, with traders debating whether the supply shock will lift crude prices. The Venezuela oil agreement and possible diplomatic reopening are viewed by bears as longer-term supply relief, while bulls argue infrastructure limits mean they will not quickly offset the disruption.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Escalating Iran and Strait of Hormuz tensions, along with volatile oil prices, are driving attention to Carnival as traders weigh higher fuel costs and travel disruption risks. The community is divided between bearish short-term views tied to geopolitical headlines and bullish investors citing resilient bookings, debt reduction, buybacks, dividends, and perceived undervaluation.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Upcoming quarterly earnings are the dominant catalyst, with traders focused on whether Broadcoms AI custom-chip and networking demand will support stronger guidance. Bulls expect a beat and continued momentum from OpenAI and hyperscaler projects, while bears argue expectations are already elevated and remain concerned about debt, potential Google-related share loss, and another post-earnings selloff.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Positive Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia, including substantial triglyceride reductions and fewer acute pancreatitis events, are driving attention and expectations for a broader regulatory filing. Traders are broadly bullish on REDEMPLOs commercial potential and Arrowheads RNAi platform, although some debate the valuation, competition from Ionis, and the stocks volatile sell-the-news trading.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Canadian government funding for Xanadus quantum-manufacturing Project OPTIMISM is driving attention, while traders debate whether additional federal and Ontario support will materialize. The community is split between viewing the backing as validation of Xanadus photonic technology and warning that heavy cash burn, limited revenue, and potential dilution could offset the benefit.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tuesday Sector Leaders: Drugs, Gas Utilities

In trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day.

Also showing relative strength are gas utilities shares, up...

Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Approximately 4.0% of the company's stock are...

Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Monday...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Wall Street Zen lowered Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday...

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of...

Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report issued on Tuesday, March...

Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average...

FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright upped their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Pyxis Oncology Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.23
Prev Close	$3.32
Open	$3.32
Dividend Yield	0.00%
50-Day Moving Average	$2.82
Beta	1.41
Avg. Volume	1.03M
PE Ratio	-2.30

52-Week High	$5.55
52-Week Low	$1.03
Market Capitalization	$269.41M
EPS (Annual)	-$1.28
Price to Book	17.91
Revenue Per Employee	$247,464.29

Feed

News

Sentiment

Earnings

Fundamentals

Info